Document Detail


Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia.
MedLine Citation:
PMID:  22532399     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Although L-asparaginase (ASP) is associated with several toxicities, its myelosuppressive effect has not been well characterized. On DFCI ALL Consortium Protocol 05-01 for children with newly diagnosed acute lymphoblastic leukemia, the Consolidation phase and the initial portion of the Continuation phase were identical for standard risk patients, except ASP was given only during Consolidation. Comparing the two treatment phases revealed that low blood counts during Consolidation with ASP resulted in more dosage reductions of 6-mercaptopurine and methotrexate. The myelosuppressive effect of ASP should be considered when designing treatment regimens to avoid excessive toxicity and dose reductions of other critical chemotherapy agents.
Authors:
Reid Merryman; Kristen E Stevenson; William J Gostic; Donna Neuberg; Jane O'Brien; Stephen E Sallan; Lewis B Silverman
Related Documents :
22665539 - Outcome of children with metastatic medulloblastoma treated with carboplatin during cra...
22366409 - The importance of applying a sentinel lymph node mapping algorithm in endometrial cance...
24490019 - Rituximab is associated with improved survival in burkitt lymphoma: a retrospective ana...
9105869 - Uterine sarcoma: the hacettepe hospital experience of 88 consecutive patients.
9740549 - Phase ii study of ci-980 (nsc 635370) in patients with previously treated advanced soft...
22300569 - Prognostic value of subclassification using mri in the t4 classification nasopharyngeal...
11601139 - Cytogenetic findings in lymphoplasmacytic lymphoma/waldenström macroglobulinemia. chro...
18730089 - Trophoblastic tumors of the uterus-problems of methotrexate therapy.
7657129 - Role of adjuvant therapy in surgically resected colorectal carcinoma.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study     Date:  2012-04-24
Journal Detail:
Title:  Pediatric blood & cancer     Volume:  59     ISSN:  1545-5017     ISO Abbreviation:  Pediatr Blood Cancer     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-09-13     Completed Date:  2012-11-30     Revised Date:  2013-06-21    
Medline Journal Info:
Nlm Unique ID:  101186624     Medline TA:  Pediatr Blood Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  925-7     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Wiley Periodicals, Inc.
Affiliation:
Harvard Medical School, Boston, Massachusetts, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
6-Mercaptopurine / administration & dosage,  adverse effects
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*,  adverse effects
Asparaginase / administration & dosage*,  adverse effects
Child
Child, Preschool
Female
Humans
Infant
Methotrexate / administration & dosage,  adverse effects
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Grant Support
ID/Acronym/Agency:
P01 CA068484/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
50-44-2/6-Mercaptopurine; 59-05-2/Methotrexate; EC 3.5.1.1/Asparaginase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Iridium-Catalyzed Enantioselective Hydrogenation of Alkenylboronic Esters.
Next Document:  Prediction of successful labor induction using transvaginal sonographic cervical measurements.